Galectin Therapeutics Inc.
GALT
NSC
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
1.95
USD
-0.01
(-0.51%)
Optionable: Yes Market Cap: 124 M 90-day average vol: 54,698
Previous close: 1.96 Open: 1.95 Bid: 1.94 Ask: 2.01
52 week range
1.02 2.47
Last updated: Friday 1st December 2023
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
🎉 Exciting news! 🎉
You are invited to join our Discord Channel.
Interact, learn, and grow with experts in the markets!
Join our DiscordFinancials
GALT Income Statement
Annual
| Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| AccretionOnPreferredStock | 229000.0 | 229000.0 | 229000.0 | 173000.0 | ||||||
| AccruedPreferredStockDividends | 10 M | 943000.0 | 868000.0 | 741000.0 | 1 M | 1 M | 7 M | 137000.0 | 171000.0 | 97000.0 |
| Basic EPS from continuing operations | -0.41 | |||||||||
| Basic EPS total | -0.41 | -0.52 | -0.65 | |||||||
| Basic weighted shares outstanding | 17 M | 22 M | 24 M | 29 M | 36 M | 39 M | 52 M | 57 M | 59 M | 59 M |
| Diluted EPS total | -1.3 | -0.78 | -0.88 | -0.76 | -0.49 | -0.38 | -0.39 | -0.41 | -0.52 | -0.65 |
| Diluted normalized net income/share | -0.39 | -0.41 | ||||||||
| Diluted weighted shares outstanding | 9 M | 20 M | 23 M | 28 M | 33 M | 37 M | 52 M | 57 M | 59 M | 59 M |
| Earnings from equity interest | -400000.0 | |||||||||
| EarningsFromEquityInterestNetOfTax | -400000.0 | |||||||||
| GainOnSaleOfSecurity | 138000.0 | 557000.0 | ||||||||
| GeneralAndAdministrativeExpense | 6 M | 7 M | 7 M | 6 M | 5 M | 7 M | 6 M | 5 M | 6 M | 7 M |
| Income before tax | -12 M | -16 M | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -31 M | -39 M |
| Interest income | 16000.0 | 42000.0 | 104000.0 | 45000.0 | 24000.0 | 38000.0 | 231000.0 | 66000.0 | 3000.0 | 52000.0 |
| InterestExpenseNonOperating | 12000.0 | 336000.0 | 87000.0 | 87000.0 | 489000.0 | 1 M | ||||
| MiscOtherSpecialCharges | -138000.0 | -557000.0 | ||||||||
| Net income from total operations | -12 M | -16 M | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -31 M | -39 M |
| NetIncomeCommonStockholders | -22 M | -17 M | -21 M | -22 M | -17 M | -15 M | -20 M | -24 M | -31 M | -39 M |
| NetIncomeContinuousOperations | -12 M | -16 M | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -31 M | -39 M |
| NetNonOperatingInterestIncomeExpense | 16000.0 | 42000.0 | 104000.0 | 45000.0 | 12000.0 | -298000.0 | 144000.0 | -21000.0 | -486000.0 | -981000.0 |
| Operating income | -12 M | -15 M | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -30 M | -38 M |
| Operating income before depreciation (EBITDA) | -12 M | -16 M | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -30 M | -38 M |
| OperatingExpense | -12 M | -15 M | -20 M | -21 M | -16 M | -14 M | 13 M | 23 M | -30 M | -38 M |
| Other income net | 400000.0 | -138000.0 | -557000.0 | |||||||
| OtherGandA | 6 M | 7 M | 7 M | 6 M | 5 M | 7 M | 6 M | 5 M | 6 M | 7 M |
| OtherunderPreferredStockDividend | 10 M | 1 M | 1 M | 914000.0 | 1 M | 1 M | 7 M | 137000.0 | 171000.0 | 97000.0 |
| PreferredStockDividends | 10 M | 1 M | 1 M | 914000.0 | 1 M | 1 M | 7 M | 137000.0 | 171000.0 | 97000.0 |
| RentAndLandingFees | 6 M | 7 M | 7 M | 6 M | 5 M | 7 M | 6 M | 7 M | ||
| Research & development expense | 6 M | 8 M | 13 M | 15 M | 12 M | 6 M | 7 M | 18 M | 24 M | 32 M |
| ResearchExpense | 6 M | 8 M | 13 M | 15 M | 12 M | 6 M | 7 M | 18 M | 24 M | 32 M |
| SalariesAndWages | -4 M | -4 M | -4 M | -2 M | -2 M | -2 M | -3 M | |||
| Selling Gen & administrative expense | 6 M | 7 M | 7 M | 6 M | 5 M | 7 M | 6 M | 5 M | 6 M | 7 M |
| Total Income available for interest expense (EBIT) | -12 M | -16 M | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -30 M | -38 M |
| Total common shares outstanding | 22 M | 24 M | 29 M | 34 M | 38 M | 46 M | 57 M | 57 M | 59 M | 59 M |
| Total net income | -12 M | -16 M | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -31 M | -39 M |
| Total ordinary shares | 60 M | 60 M | 60 M | 60 M | 60 M | 60 M | 60 M | 60 M | 60 M | 60 M |
| TotalExpenses | -12 M | -15 M | -20 M | -21 M | -16 M | -14 M | 13 M | 23 M | -30 M | -38 M |
Call: 1-877-778-8358
Welcome! I'm Ankur, the founder/CEO of MarketXLS. With over six years of experience, I've helped 2500+ customers implement personalized investment research strategies and monitoring systems in Excel.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.
Get started today
Get started today